In imatinib-resistant CML, it has been shown that the knockdown of BCR-ABL decreased the levels of SIRT1 and FoxO1 proteins and increased the levels of Ac-FoxO1 and p53 proteins, indicating that SIRT1 is downstream of BCR-ABL [55]. Here, TP53 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.